Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney Disease
Finerenone (Kerendia) prevents cardiovascular (CV) and some renal events in type 2 diabetes patients with earlier stages of kidney disease, the FIGARO-DKD trial showed. In the trial’s stage 1 to 4 kidney disease patients with moderate-to-severe albuminuria, the nonsteroidal mineralocorticoid receptor antagonist (MRA) reduced the composite of CV death, nonfatal myocardial infarction or stroke, or […]
Finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes
Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. That’s the finding of late breaking research presented in a Hot Line session today at ESC Congress 20211 and published in the New England Journal of Medicine2. Diabetic kidney disease develops in approximately 40% of patients […]
Finerenone OK’d for Slowing Kidney Disease in T2D
The FDA approved the anti-mineralocorticoid agent finerenone (Kerendia) for slowing the progression of chronic kidney disease in type 2 diabetes patients, the agency announced on Friday. The first non-steroidal, selective mineralocorticoid receptor antagonist was approved to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, […]